BioInvent International AB (publ) provided revenue guidance for the year 2019. For the period, the company signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP compliant material to support their clinical development programs, which is expected to generate revenue of approximately USD 1.5 million.